Bioverge
VC Fund
San Francisco, United States
Bioverge is a venture capital firm specializing in emerging healthcare startups. The firm operates Bioverge.com, an investment platform that aims to democratize access to startups solving healthcare’s biggest challenges and accelerate their progress.
- Total investments:
- 59
- Last investment:
- Lead investor:
- 0%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Bioverge invests in
BiotechnologyHealth CareTherapeuticsLife ScienceMedical
Stages Bioverge invests in
SeedSeries ASeries BVenture - Series UnknownSeries C
Countries Bioverge invests in
United StatesIrelandUnited Kingdom
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Biotechnology 25 (42%)
- Health Care 19 (32%)
- Therapeutics 12 (20%)
- Life Science 8 (14%)
- Medical 6 (10%)
Stage
- Seed 29 (49%)
- Series A 9 (15%)
- Series B 5 (8%)
- Venture - Series Unknown 3 (5%)
- Series C 1 (2%)
Country
- United States 37 (63%)
- Ireland 1 (2%)
- United Kingdom 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Marianne Santaguida
Entrepreneur In Residence
|
Entrepreneur In Residence | Total investments: 0 | Find email | |
Neil Littman
Founding Partner & CEO
|
Founding Partner & CEO | Total investments: 0 | Find email | |
Rick Gibb
Founding Partner & COO
|
Founding Partner & COO | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| EnClear Therapies is a Cambridge (USA) based life sciences company developing a device-based therapy to aid in the treatment of neurodegenerative disease and delivery and monitoring of cerebrospinal fluid (CSF). EnClear’s proprietary therapeutic platform focuses on removing toxic proteins from the CSF. The company’s first products will targetimproving the lives of patients with Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP). | Venture - Series Unknown / Sep 03, 2024 | ||
| Established in 2016, UBERDOC provides priority access to the best doctors for an affordable, transparent price. The company offers free directory listing to qualified Medical Doctors and free membership to patients. Its unrivaled mobile technology and transparent pricing structure make it simple and easy for patients needing urgent medical care toinstantly connect to a choice of specialists without requiring a referral, insurance paperwork or having to wait many months for an appointment. The Boston-based, privately held company was founded by Paula Muto, MD, FACS, a Vascular and General Surgeon. Muto has been credited as an expert in the healthcare industry by publications like Huffington Post, Fox business, Becker’s Hospital Review, General Surgery News, and Boston magazine.UBERDOC, Inc., a digital platform for direct-pay healthcare, has grown from a Boston-based startup to a nationally recognized member of the digital health community, having participated in several conferences in Boston, New York, Chicago and San Francisco. Thousands of doctors across the US are enrolled on the UBERDOC platform with patients using its service daily.At www.uber-docs.com (https://uber-docs.com/), patients search by medical specialty, book and pay for a doctor appointment using an HSA (Health Savings Account), FSA or credit card, and see the Medical Doctor at the scheduled time and place. A $50 transaction fee secures the appointment, and $250 is charged after the consult is determined completed by the doctor. Doctors are paid immediately and directly through the UBERDOC platform. | Venture - Series Unknown / Jul 09, 2024 | ||
| My Diabetes Tutor was recently named the first accredited diabetes education telehealth program in California by the American Association of Diabetes Educators (AADE), a National Accredited Organization (NAO). This will provide individuals with diabetes increased access to high quality diabetes education services. My Diabetes Tutor was named thefirst accredited diabetes education telehealth program in California by the Association of Diabetes Care and Education Specialists (ADCES), (etc). My Diabetes Tutor recently did a scientific presentation at the American Diabetes Association Scientific Meeting 2022 and our abstract is published in the Diabetes Journal. | Jul 27, 2023 | ||
| My Diabetes Tutor was recently named the first accredited diabetes education telehealth program in California by the American Association of Diabetes Educators (AADE), a National Accredited Organization (NAO). This will provide individuals with diabetes increased access to high quality diabetes education services. My Diabetes Tutor was named thefirst accredited diabetes education telehealth program in California by the Association of Diabetes Care and Education Specialists (ADCES), (etc). My Diabetes Tutor recently did a scientific presentation at the American Diabetes Association Scientific Meeting 2022 and our abstract is published in the Diabetes Journal. | $3M / Seed / Jul 27, 2023 | ||
| Modulo Bio simulates the neuroimmune system to find medication candidates that target microglia cells. The organization's proprietary neuroimmune platform combines the most recent developments in stem cell biology and neuroscience with software, automation, and artificial intelligence to create novel treatments. | $8M / Seed / Jun 01, 2023 | ||
| Jelikalite creates medical equipment for kids with autism spectrum disorders. They emphasize using non-invasive innovative methods to promote the brain health of children. It is a wearable medical device. It combines infrared light, sensors, an AI personalization platform, and non-invasive brain stimulation. | Seed / Feb 01, 2023 | ||
| Jelikalite creates medical equipment for kids with autism spectrum disorders. They emphasize using non-invasive innovative methods to promote the brain health of children. It is a wearable medical device. It combines infrared light, sensors, an AI personalization platform, and non-invasive brain stimulation. | Seed / Dec 21, 2022 | ||
| Eigen Therapeutics is a biotechnology company on a mission to make therapies that make cancer easier to find and eliminate. Eigen is focused on the development of “priming” therapies, therapies that help targeted therapies reach their full potential by addressing cancer heterogeneity, making cancer cells more vulnerable and/or making healthycells more resilient to treatment. Eigen is building a high-throughput discovery platform to explore the space of priming therapies, leveraging proprietary machine learning algorithms to discover novel associations, new classes of drugs, and new potential therapies that change a cell's state to make it more vulnerable to a targeted therapy. The Eigen platform represents the intersection of biology and engineering, and includes robotic systems, laboratory operations software, and machine learning analysis pipelines—all developed in-house—with the ultimate goal of saving more lives. | $7M / Seed / Dec 08, 2022 | ||
| GigaMune was founded as a spin-out from GigaGen in 2017. They are combining unique insight into T cell responses to tumors with massively parallel T cell receptor (TCR) discovery to develop the next generation of T cell therapies. | Seed / Dec 01, 2022 | ||
| Notable Labs is a personalized testing service for cancer patients that prioritizes combinations of FDA-approved treatments that can be immediately prescribed by a doctor without a clinical trial. | $189.2K / Series B / Jul 01, 2022 | ||
| See all 59 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
Life Science Investors
6,823 investors
Health Care VC Funds
32,370 investors
Biotech VC Funds
18,864 investors
Biotechnology VC Funds
17,016 investors
Medical VC Funds
16,214 investors
FAQ
What does Bioverge invest in?
Bioverge invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Seed and Series A stage. Most of the 59 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Bioverge?
Public channels for Bioverge include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Bioverge?
The team at Bioverge includes Marianne Santaguida (Entrepreneur In Residence), Neil Littman (Founding Partner & CEO) and Rick Gibb (Founding Partner & COO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
